<DOC>
	<DOCNO>NCT02348528</DOCNO>
	<brief_summary>CC5013-MM024 multicenter , open-label , Extended Access Program ( EAP ) lenalidomide plus low dose dexamethasone regimen Chinese subject relapse refractory MM participate Study CC-5013-MM-021 . For subject remain progression free Rd treatment Study CC-5013-MM-02 1 , LAP offer option continue lenalidomide treatment subject show therapeutic benefit .</brief_summary>
	<brief_title>Open-label Extended Access Program Lenalidomide Plus Dexamethasone Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated CC-5013-MM021 Least 1 Year</brief_title>
	<detailed_description>After subject still treatment complete least 1 year therapy Study CC-5013-MM-021 ( start date lenalidomide treatment ) , EAP allow consent subject ( 1 ) remain progression free Rd treatment Study CC-SO I3-MM-02 I roll Treatment Phase LAP continue Rd treatment , ( 2 ) discontinue Rd therapy currently Long-Term Follow-up Phase Study CC-5013-MM-021 roll Safety Follow-up Phase EAP survival SPM outcomes . The maximum duration LAP program least 5 year time last on-study</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects discontinue treatment remain longterm followup CC5013MM021 study require sign inform consent document ( ICD ) roll Safety Followup Phase Extended Access Program ( EAP ) . These subject require screen eligibility must agree follow survival Second Primary Malignancy ( SPM ) minimum every 4 month ( Â± 7 day ) interval least 5 year time last onstudy subject enrol Study CC5013MM021 . Subjects consent Treatment Phase EAP must meet follow criterion continue therapy receive Study CC5013MM021 : 1 . Completed least 1year lenalidomide plus lowdose dexamethasone ( Rd ) treatment remain progression free Rd treatment Study CC5013MM021 time screen visit EAP . 2 . Able adhere study visit schedule , compliance study drug protocol requirement Study CC5013MM024 . 3 . Consented EAP protocol . 4 . Must agree comply Pregnancy Prevention requirement . 5 . Females childbearing potential ( FCBP ) 1 : Must agree use , able comply , least 2 form reliable contraception simultaneously practice complete abstinence heterosexual intercourse without interruption , transferring/rolling CC5013MM021 study , screen visit eligibility , throughout study drug therapy ( include dose interruption ) 28 day end study drug therapy , even amenorrhea . This apply even subject practice complete continue abstinence confirm monthly basis . Must agree medically supervised pregnancy test minimum sensitivity 25 IU/mL ( i.e. , negative pregnancy test ) screening eligibility every 28 day study . For FCBP , pregnancy test must continue frequency MM021 study . If regular menstrual cycle , must agree ongoing pregnancy test course study ( every 28 day ) , dose interruption , study discontinuation 28 day follow study drug discontinuation . If menstrual cycle irregular , pregnancy test must occur every 14 day study , study discontinuation 14 28 day follow study drug discontinuation . This requirement also apply female childbearing potential practice complete continue sexual abstinence . Must agree breastfeed study drug therapy least 28 day follow study drug discontinuation . 6 . Male subject : Must agree use condom sexual contact FCBP , even vasectomy , throughout study drug therapy , dose interruption least 28 day follow study drug discontinuation . Must agree donate semen sperm study drug therapy least 28 day follow study drug discontinuation . Subjects positive finding pregnancy test screen eligible Treatment Phase EAP consent Safety Followup Phase EAP . Subjects continue treatment discretion physician follow criterion occur treatment CC5013MM021 study Screening Phase . All subject eligible continue treatment enter Safety Followup Phase : 1 . Serious hypersensitivity anaphylaxis lenalidomide dexamethasone . 2 . Serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent document . 3 . Any condition , include presence serious laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Previously discontinue lenalidomide treatment due toxicity . 5 . Newly diagnose malignancy Multiple Myeloma ( MM ) , except follow : Basal cell carcinoma skin Squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast Incidental histologic find prostate cancer ( T1a T1b use tumor , node , metastasis [ TNM ] clinical staging system ) prostate cancer curative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>open-label</keyword>
	<keyword>CC-5013-MM-021</keyword>
</DOC>